

## Genetic Analysis of Varicella-Zoster Virus ORF0 to ORF4 by Use of a Novel Luciferase Bacterial Artificial Chromosome System<sup>∇</sup>

Zhen Zhang,<sup>1</sup> Jenny Rowe,<sup>2</sup> Weijia Wang,<sup>1</sup> Marvin Sommer,<sup>3</sup> Ann Arvin,<sup>3</sup>  
Jennifer Moffat,<sup>2</sup> and Hua Zhu<sup>1\*</sup>

*Department of Microbiology and Molecular Genetics, UMDNJ-New Jersey Medical School, 225 Warren Street, Newark, New Jersey 07101<sup>1</sup>; Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York 13210<sup>2</sup>; and Department of Pediatrics and Microbiology and Immunology, Stanford University, 300 Pasteur Drive, Stanford, California 94305-5208<sup>3</sup>*

Received 2 December 2006/Accepted 11 June 2007

**To efficiently generate varicella-zoster virus (VZV) mutants, we inserted a bacterial artificial chromosome (BAC) vector in the pOka genome. We showed that the recombinant VZV (VZV<sub>BAC</sub>) strain was produced efficiently from the BAC DNA and behaved indistinguishably from wild-type virus. Moreover, VZV's cell-associated nature makes characterizing VZV mutant growth kinetics difficult, especially when attempts are made to monitor viral replication in vivo. To overcome this problem, we then created a VZV strain carrying the luciferase gene (VZV<sub>Luc</sub>). This virus grew like the wild-type virus, and the resulting luciferase activity could be quantified both in vitro and in vivo. Using PCR-based mutagenesis, open reading frames (ORF) 0 to 4 were individually deleted from VZV<sub>Luc</sub> genomes. The deletion mutant viruses appeared after transfection into MeWo cells, except for ORF4, which was essential. Growth curve analysis using MeWo cells and SCID-hu mice indicated that ORF1, ORF2, and ORF3 were dispensable for VZV replication both in vitro and in vivo. Interestingly, the ORF0 deletion virus showed severely retarded growth both in vitro and in vivo. The growth defects of the ORF0 and ORF4 mutants could be fully rescued by introducing wild-type copies of these genes back into their native genome loci. This work has validated and justified the use of the novel luciferase VZV BAC system to efficiently generate recombinant VZV variants and ease subsequent viral growth kinetic analysis both in vitro and in vivo.**

Varicella-zoster virus (VZV) is a human alphaherpesvirus that is a significant pathogen in the United States. Primary infection of VZV typically occurs during childhood and leads to varicella (chickenpox). Like all herpesviruses, VZV establishes lifelong latency in the host, specifically in trigeminal ganglia and dorsal root ganglia. The end sequela of VZV reactivation is herpes zoster (shingles), which is characterized by a painful vesicular rash of dermatomes that can lead to chronic postherpetic neuralgia (1, 10).

Beginning in 1995, the U.S. government recommended vaccination of all children with the attenuated Japanese Oka varicella virus (vOka) (28). This has significantly improved prophylaxis against varicella infection. The effectiveness of the vaccination in children is estimated to be between 72% and 98% (11). However, breakthrough rates of varicella have been calculated to be between 2% and 34% (11). As a result of the vaccine recommendation, there is speculation that a rise in herpes zoster in older adults may occur because of less exposure to wild-type VZV to boost natural immunity (30).

Despite the success in preventing and controlling VZV infection, many aspects of its pathogenesis are not completely understood. VZV possesses the smallest genome among all human herpesviruses; it contains a DNA genome of 125 kb that bears 70 unique open reading frames (ORFs). Although

many of its ORF products have amino acid sequences homologous to those of herpes simplex virus type 1, less than 20% of the VZV genome has been functionally characterized. This lack of knowledge is partly due to the difficulty of generating mutants to investigate gene function and the long period of time needed to establish pure clones using conventional techniques with mammalian cells. A more detailed understanding of the molecular biology, replication, and pathogenesis of VZV will aid in discovering optimal prophylactic compounds and vaccine strains and in improving therapeutic regimens for varicella infection and zoster.

In recent years, a major advance in VZV genetics was the cloning of overlapping segments of the VZV genome into four cosmids (6, 21). This system allows the creation of recombinant VZV by cotransfection of four overlapping cosmids, one of which can contain a mutation in a desired ORF, representing the entire genome of the parental Oka (pOka) strain. An attractive alternative for generating recombinant VZV is the recent development of the VZV bacterial artificial chromosome (VZV<sub>BAC</sub>) (18). The BAC technology provides easy and efficient manipulation of the viral genome and rapid isolation of these recombinant viruses (2).

Other obstacles in understanding VZV pathogenesis include its narrow host range and the dramatic differences in its replication cycles when studied in vitro versus in vivo (1, 8). For instance, VZV infection is highly cell associated in cell culture. In contrast, as observed with human tissue biopsy samples, VZV propagates by both lytic (release of cell-free virus) and cell-to-cell infection. Thus, merging the observations from in vitro and in vivo studies may be difficult. Various in vitro and

\* Corresponding author. Mailing address: Department of Microbiology and Molecular Genetics, UMDNJ-New Jersey Medical School, 225 Warren Street, Newark, NJ 07101-1709. Phone: (973) 972-4483, ext. 2-6488. Fax: (973) 972-8981. E-mail: zhuhu@umdnj.edu.

<sup>∇</sup> Published ahead of print on 20 June 2007.

in vivo systems have been developed to analyze VZV replication and pathogenesis. In addition to various cell lines (26), intact portions of human organs provide a more relevant environment with which to study VZV pathogenesis, because they allow VZV infection to be studied in fully differentiated human cells in their normal tissue architecture and microenvironment. Development of the model of the severe combined immunodeficient mouse with human tissue xenograft (SCID-hu) greatly facilitates investigation of VZV pathogenesis in vivo. Results from histopathological studies have shown that this tissue graft strategy is an accurate representation of VZV pathogenesis in human tissues (1, 3, 13, 33). Additionally, an ex vivo human skin organ culture for VZV skin tropism was recently developed (29).

In the present study, the full-length pOka genomic DNA was first cloned as a BAC, and then a luciferase gene was inserted into this viral genome. The BAC DNA isolated from *Escherichia coli* was used to transfect human MeWo cells to generate a luciferase-expressing VZV (VZV<sub>LUC</sub>) strain. This VZV<sub>LUC</sub> strain grows normally and can be monitored both in vitro and in vivo by enzyme activity. Using the highly efficient bacterial recombination system, five VZV ORFs, from ORF0 to ORF4, were deleted individually, and their functions for viral replication were analyzed in both in vitro and in vivo systems.

#### MATERIALS AND METHODS

**Cells, cosmids, and viruses.** Human melanoma (MeWo) cells and primary human foreskin (HF) fibroblasts were grown in Dulbecco's minimal essential medium supplemented with 10% fetal calf serum, 100 U of penicillin-streptomycin/ml, and 2.5 µg of amphotericin B/ml as previously described and used to propagate VZV (15, 17) in vitro. Each of the four cosmids, pvFsp73, pvSpe14, pvPme19, and pvSpe23, contains overlapping genomic DNA fragments of VZV derived from the pOka clinical isolate previously described (21). Recombinant pOka virus was derived by cotransfection of these four cosmids (21).

**Plasmids.** A BAC vector, pUSF-3, was described in reference 15. pUSF-4 was constructed by removing a ClaI site from the green fluorescent protein (GFP) expression cassette of pUSF-3. pUSF-5 was formed by digesting pUSF-4 with HindIII to remove two human cytomegalovirus (HCMV) fragments and religation of the plasmid. pUSF-6 was constructed from pUSF-5 by inserting two fragments of VZV DNA with added sequences for BamHI, HindIII, and LoxP sites. PCR primers were designed to amplify two fragments of ~500 bp between ORF60 and ORF61 of the VZV pOka strain at genomic sites 102080 to 102560 and 102564 to 103039 (NCBI nucleotide accession no. AB097933). The four primers are 5'-GGA TCC AAC GTA CCC CAA ACT TAA AAC GCT C and 5'-AAG CTT ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA TAT TAA AAT GGC CGG AAG GTG GCG G; and 5'-AAG CTT ATA ACT TCG TAT AAT GTA TGC TAT ACG AAG TTA TAA CTT TAA TTG CTA TAA GAC ATA CCC AAA C and 5'-GGA TCC TGT TGG GAG GGG GAA GGA AAT CG. The fragments were then cloned separately into pCR4-TOPO (Invitrogen), sequenced to verify the products, digested with BamHI and HindIII, and finally combined in a triple ligation into pUSF-5 at the HindIII site, creating pUSF-6. pGEM-T TA cloning vector was purchased from Promega (Madison, WI). pGEM-lox-zeo was used for rescue virus generation as described in reference 20. pGL3-hyg was derived from plasmid pGL3-control (Promega) by replacing its simian virus 40 (SV40) enhancer sequence with a hygromycin resistance gene expression cassette from pIJ963 (a gift from Issar Smith). pGEM-oriV/kan1 was described in reference 31.

**Construction of the VZV BAC clone.** The cosmid pvSpe23 was transfected into *E. coli* strain DY380 (27, 32). Electrocompetent DY380 cells were prepared after incubating log-phase cells at 42°C for 15 min as described previously (31, 32). pUSF-6 was linearized by digestion with BamHI and transfected into DY380 cells containing pvSpe23, and recombinant clones were selected on LB plates with 12.5 µg/ml chloramphenicol. The resulting BAC vector-containing cosmid DNA, pvSpe23-pUSF6, along with three other cosmids, pvFsp73, pvSpe14, and pvPme19, were linearized by digestion with AscI and mixed in water to final concentrations of 100 ng/µl for pvFsp73, pvSpe14, and pvPme2 and 50 ng/µl for pvSpe23-pUSF6. Transfections were done with MeWo cells by using 30 µl of

the cosmid mixture in 31.5 µl of 2 M CaCl<sub>2</sub> in water and HEPES-buffered saline (14). Green fluorescent plaques were visualized using fluorescent microscopy. Infected cells were split twice at a ratio of 1:3 to allow the virus to spread through the monolayer. The circular VZV DNA containing the BAC vector was isolated from infected MeWo cells and transfected into *E. coli* (Gene Hogs, Invitrogen, Carlsbad, CA), and transformants resistant to chloramphenicol were selected as described previously (15). BAC DNA from the resulting colonies was purified from 4-ml cultures, and the full-length VZV genomic DNA in these clones was verified by HindIII digestion and restriction fragment length polymorphism analysis.

**Generation of VZV<sub>BAC</sub> from BAC DNA isolated from *E. coli*.** *E. coli* DY380 with VZV<sub>BAC</sub> was cultured in 500 ml of LB medium with 12.5 µg/ml chloramphenicol at 32°C for 20 h. VZV<sub>BAC</sub> DNA was isolated using a Nucleobond Maxiprep BAC DNA isolation kit (BD Biosciences, Palo Alto, CA) and used to transfect MeWo cells by using FuGene6 transfection reagent (Roche, Indianapolis, IN) according to the manufacturer's standard protocol. The ratio of DNA to transfection reagent was 1.5 µg:6 µl for a transfection reaction mixture in a well (35 mm) of six-well plates. VZV plaques were normally visualized after 3 days posttransfection. To remove the BAC vector (flanked by two *loxP* sites) from the VZV genome, a Cre expression vector was cotransfected with VZV BAC DNA as described in reference 15.

**Construction of VZV<sub>LUC</sub>.** To generate VZV<sub>LUC</sub>, the 100-bp sequence between ORF65 and ORF66 was replaced with a luciferase-hygromycin-resistant gene (Hyg<sup>r</sup>) cassette in which the luciferase gene is driven by an SV40 early promoter by homologous recombination. The luciferase-Hyg<sup>r</sup> expression cassette was amplified from the pGL3-hyg plasmid by PCR using a QIAGEN Hotstar DNA polymerase kit and two primers (5'-GTC AGC TAT ACC GAC ATT CTC ACA AAG AGG TAA AGT TAC CCG AGC TCT TAC GCG TGC TAG and 5'-TGA CAA AAA GGG GAG GGG TTA AAC ATA ACT TAC AAA TAT GTC AGG CGC CGG GGG CGG TGT). This PCR product contained a luciferase-Hyg<sup>r</sup> cassette flanked by the 40-bp homologous sequences targeting the interval sequence between ORF65 and ORF66. PCR product was digested with DpnI (New England Lab) and purified by using a PCR purification kit (QIAGEN). About 200 ng of PCR product was transformed via electroporation at 1.6 kV and 250 µF by using a Bio-Rad Gene Pulser II in *E. coli* DY380 carrying the VZV<sub>BAC</sub>. The recombinants were selected on agar plates containing 50 µg/ml hygromycin (Sigma) at 32°C.

**Construction of ORF0 to ORF4 deletion mutant viruses.** To delete each ORF, two primers were designed to contain 20 bp of nucleotides homologous to the kanamycin resistance gene (Kan<sup>r</sup>) cassette and 40 bp of nucleotides homologous to the flanking sequences adjacent to either the start or stop codon of the ORF being targeted for deletion. These primers for deletion include the following sequences: for ORF0, 5'-AAC CCG CGC CTT TTG CGT CCA CCC CTC GTT TAC TGC TCG GGC TCT TGT TGG CTA GTG CGT A and 5'-GCA AGC GAG AAT AAA TAC CTT CCC CTT CCG GAC AGT AGT TTC TGC CAG TGT TAC AAC CAA; for ORF1, 5'-ACT CAA CTA CAT GAA ACT ACT GTC CGG AAG GGG AAG GTA TGC TCT TGT TGG CTA GTG CGT A and 5'-ATA AGC AAA TCC TGT TAA TAT TAT TTT GGG ATC CGC ATC TGC CAG TGT TAC AAC CAA; for ORF2, 5'-TAA TAG CTA TTA TCG TAA CCC ACC CCC GTA AAA TCA TAA AGC TCT TGT TGG CTA GTG CGT A and 5'-AAA TAC GTA CAA TCG AAA AAA GGT GTA TTT TAT TTA GTG ATC TGC CAG TGT TAC AAC CAA; for ORF3, 5'-CTT TTT TCG ATT GTA CGT ATT TTT ATT TAA ATG TGT AGT TGC TCT TGT TGG CTA GTG CGT A and 5'-GGG TAA AAC ACA CAC CAG ACG TGT ACC GAA CGT TTA ATT ATC TGC CAG TGT TAC AAC CAA; and for ORF4, 5'-TTA GTA TGT TTT GAG AAG CAT GAA AAA GGT ATT TTT TAT TGC TCT TGT TGG CTA GTG CGT A and 5'-AGG CAA CTG CAA ACA CGC AAT TGT CAG ATA TTT TGC AGC CTC TGC CAG TGT TAC AAC CAA. The Kan<sup>r</sup> cassette was amplified from the plasmid pGEM-oriV/kan1. PCR products were digested with DpnI and purified by a gel extraction kit (QIAGEN). About 200 ng of each PCR product was transformed into the DY380 cells carrying the VZV<sub>LUC</sub> BAC via electroporation under the conditions described above. The recombinants were selected on agar plates containing 30 µg/ml kanamycin (Sigma) at 32°C. VZV mutant DNA was isolated from *E. coli* and verified by the HindIII digestion patterns and PCR analysis and then were transfected into MeWo cells to produce mutant VZV viruses as described above.

**Construction of rescue viruses for ORF0 and ORF4.** To generate rescue viruses, ORF0 and ORF4 were amplified by PCR using an Invitrogen high-fidelity Platinum Taq DNA polymerase kit and cloned into the plasmid pGEM-lox-zeo between the NotI and BglII sites for ORF0 and between the SpeI and NdeI sites for ORF4 to form pGEM-zeo-ORF0 and pGEM-zeo-ORF4, respectively. Both cloned fragments were verified by sequencing analysis, and no coding errors were introduced into these ORFs by PCR amplification. Then, the zeocin




FIG. 1. Construction of VZV<sub>BAC</sub>. (A) A BAC vector, pUSF-6, contains the prokaryotic replication origin (*ori*) gene, the replication and partition (*repE*, *parA*, and *parB*) genes, the Cam<sup>r</sup> gene, a green fluorescent protein (*gfp*) gene, two 500-bp VZV fragments (gray bars a and b), and two *loxP* sites (two white bars). To insert this BAC vector into a VZV cosmid, pUSF-6 was digested by BamHI, resulting in a linear fragment. (B) Schematic diagram of the VZV pOka genome shows that VZV contains a 125-kb genome with unique long (UL) and unique short (US) segments. Four cosmids containing overlapping VZV genomic segments are shown below the diagram. pUSF-6 was inserted between ORF60 and ORF61 in a VZV cosmid, pvSpe23, by homologous recombination. (C) The pvSpe23 containing a BAC vector was cotransfected with three other VZV cosmids into MeWo cells, and the resulting recombinant virus was replicated and produced a green fluorescent plaque. (D) The growth curve of VZV<sub>BAC</sub> was compared to that of wild-type pOka. PFU/ml at each dpi were recorded. This result indicates that VZV<sub>BAC</sub> (green) has no detectable growth defect; it grows as well as the parental virus (red) in vitro.

resistance (Zeo<sup>r</sup>)-ORF0 cassette was amplified by PCR from pGEM-zeo-ORF0 using two primers (5'-AAC CCG CGC CTT TTG CGT CCA CCC CTC GTT TAC TGC TCG GAT GGC GAC CGT GCA CTA CTC and 5'-GCA AGC GAG AAT AAA TAC CTT CCC CTT CCG GAC AGT AGT TGG ATG GAT CCA TAA CTT CGT), and the Zeo<sup>r</sup>-ORF4 cassette was amplified by PCR from pGEM-zeo-ORF4, using two other primers (5'-TTA GTA TGT TTT GAC AAG CAT GAA AAA GGT ATT TTT TAT TGG ATG GAT CCA TAA CTT CGT and 5'-AGG CAA CTG CAA ACA CGC AAT TGT CAG ATA TTT TGC AGC CAT GGC CTC TGC TTC AAT TCC AAC). These PCR products contain 40 bp of VZV genomic adjacent sequences homologous to those of the Kan<sup>r</sup> cassettes that are located in the deleted ORF0D and ORF4D loci. The resultant PCR products were treated with DpnI and transformed into the DY380 cells carrying ORF0D and ORF4D BAC clones via electroporation as described above. The recombinants were selected on agar plates containing 50 µg/ml zeocin (Invitrogen) and 12.5 µg/ml chloramphenicol at 32°C. The correct rescue clones (ORF0R to ORF4R) were first confirmed by their antibiotic sensitivities. The correct clones should be resistant to chloramphenicol, hygromycin, and zeocin and sensitive to kanamycin and ampicillin. These clones were further confirmed by restriction digestion and PCR analysis. Maxiprep DNA was purified from each and used to transfect MeWo cells to produce the rescue viruses as described above.

**Titration and growth curve analysis.** Titers for each recombinant virus were determined by infectious focus assay. MeWo cells were seeded in six-well plates and mixed with different dilutions of infected cells. Green fluorescent VZV plaques were counted by using a fluorescent microscope, at 3 days postinfection (dpi). Growth curve analyses were carried out using two different methods. For a conventional way of using the infectious center assay, MeWo cells were mixed with 100 PFU of infected MeWo cells and seeded in six-well plates. At each day of infection, three wells of infected cells were collected, and titers were determined. The numbers of plaques from each day were averaged, and a growth curve was generated. For a growth curve using a bioluminescence assay, six-well plates of MeWo cells were infected with 100 PFU of infected MeWo cells, as described above. After 24 h of infection, D-luciferin was added to the cultured wells to a final concentration of 150 µg/ml. After a 10-min incubation at 37°C, the bioluminescence in different wells was recorded simultaneously using an in vivo imaging system (IVIS; 50 Series; Xenogen Corporation, Alameda, CA) following the manufacturer's instruction. After measurement, the luciferin-containing media were replaced by regular cell culture media. This measurement was repeated every 24 h for 7 days. Bioluminescence signals from manually defined regions of interest were quantified and analyzed by using LivingImage image analysis software (Xenogen).

**Infection of human T-cell and skin xenografts and measurement of infection in the SCID-hu mouse model.** Thymus-liver conjoint implants were engrafted in male CB-17 SCID/beige mice. The construction and use of thymus-liver implants were described in detail previously (4, 17). About 3 months after implantation,

the thymus-liver implants were surgically exposed and directly injected with  $2 \times 10^3$  to  $4 \times 10^3$  PFU of the VZV<sub>Luc</sub>-infected MeWo or HF cells (10 to 20 µl of cell suspension). VZV replication in vivo was measured using an IVIS (Xenogen). At each day postinfection, 250 µl of luciferase substrate, D-luciferin (15 mg/ml), was administered to mice by intraperitoneal injection, and bioluminescence was observed 10 min later as photon flux (photons/s/cm<sup>2</sup>/steradian) in the regions of interest above the thymus-liver implants. Human fetal skin xenografts were introduced into SCID mice subcutaneously as full-thickness dermal grafts as described previously (17). Four weeks after implantation, the VZV<sub>Luc</sub> virus was inoculated, and viral growth was monitored using an IVIS, exactly as described above.

## RESULTS

**Construction of VZV<sub>BAC</sub>.** In order to use the full power of molecular genetic techniques to efficiently isolate recombinant VZV, the pOka genome was cloned as a BAC, using a construction approach similar to that used for HCMV BAC (15). The VZV<sub>BAC</sub> was constructed from a vector, pUSF-6, that contains the prokaryotic replication origin (*ori*) gene, the replication and partition function (*repE*, *parA*, and *parB*) genes, the chloramphenicol resistance (Cam<sup>r</sup>) gene, and the GFP eukaryotic expression cassette (Fig. 1A). The pUSF-6 vector, flanked by two 500-bp VZV fragments, was inserted between ORF60 and ORF61 in VZV cosmid pvSpe23 (Fig. 1B) by homologous recombination using a highly efficient recombination system (32). Then, the BAC-containing cosmid was cotransfected with three complementary cosmids (21) into MeWo cells to generate a recombinant virus. Green fluorescent plaques were observed a few days posttransfection (Fig. 1C), indicating that the recombinant viruses harboring the BAC sequence were generated. Circular VZV DNA was purified from infected cells and transformed into *E. coli*. Two days later, many chloramphenicol-resistant colonies were obtained. The VZV<sub>BAC</sub> DNA was then isolated from *E. coli*.

**Generation and analysis of VZV<sub>BAC</sub> viruses.** The integrity and stability of VZV<sub>BAC</sub> DNA were first confirmed by restric-




FIG. 2. Generation and analysis of the VZV<sub>Luc</sub> strain. (A) Luciferase assay. MeWo cells were infected with VZV<sub>Luc</sub> or VZV<sub>BAC</sub> for 2 days, and luciferase activity was measured. The cells infected with VZV<sub>Luc</sub> showed a high level of luciferase activity, while the parental VZV<sub>BAC</sub> strain had no activity. (B) Bioluminescence measurement. Two wells of a six-well dish of MeWo cells were infected with VZV<sub>BAC</sub> (upper left), and two were infected with VZV<sub>Luc</sub> (upper right). Two days postinfection, D-luciferin substrate was added to the cultured wells, and bioluminescence was measured using IVIS imaging. Bioluminescence can be detected only in VZV<sub>Luc</sub>-infected cells. The intensities were indicated as pseudocolors, as shown by an intensity scale bar at the top; higher intensity is represented by a warmer color, and lower intensity is represented with a cooler color. The infection of these wells was verified by showing GFP-positive plaques (bottom panel). (C) Correlation of luminescence and plaque numbers. Growth curves generated by an infectious center assay (black curve and left scale) and a bioluminescence assay (green curve and right scale) were compared. (D) The growth curve comparison of VZV<sub>Luc</sub> with and without the BAC vector. MeWo cells were infected with VZV with the BAC vector (green) and without the BAC vector (blue). Their growth curves were generated by bioluminescence assay. (E) Monitoring VZV replication in vivo. SCID mice with human thymus-liver implants were inoculated with  $4 \times 10^3$  PFU VZV-infected cells. At 7 days postinfection, a luciferase substrate, D-luciferin, was injected, and bioluminescence was observed 10 min later using IVIS imaging and overlaid on the mouse images.

tion enzyme digestion. HindIII digestion of VZV<sub>BAC</sub> DNA generated the predicted digestion pattern with the sum of ~130 kb, indicating that no large deletions and rearrangements in VZV<sub>BAC</sub> DNA were detectable (see Fig. 4B, wild type [WT]). To closely examine whether base-pair changes could be detected in the VZV<sub>BAC</sub> genome after synthesis in *E. coli*, the ORF62/71 genes, which encode an immediate-early transactivating protein, were sequenced. The 3.9-kb coding sequences were amplified by PCR, cloned into pGEM-T vector, and sequenced as described previously (23). The ORF62/71 sequences in VZV<sub>BAC</sub> are identical to those of the published pOka strain (accession no. AB097933). These results suggest that the BAC DNA in *E. coli* is stable.

To make VZV from the BAC DNA, three independent VZV<sub>BAC</sub> DNA clones were transfected into MeWo cells. Many green fluorescent VZV plaques appeared from each clone at about 3 days posttransfection. To examine whether the VZV strains produced from VZV<sub>BAC</sub> DNA grew like the parental pOka virus, the growth properties of VZV<sub>BAC</sub> and pOka virus in MeWo cells were compared. The results showed that both viruses grew at a similar rate (Fig. 1D).

The stability of the GFP marker in the viral genome was also tested. MeWo cells were infected with VZV<sub>BAC</sub> and continuously passed four times (1:10 dilution) over 2 weeks. The plaques were examined using a fluorescent microscope. All

VZV-infected cells fluoresced green, suggesting that the GFP marker is stable in the viral genome.

These experiments demonstrated that VZV<sub>BAC</sub> DNA is infectious, that this method was efficient to produce stable VZV viruses, and that no growth defect was detected in the resulting viruses in vitro.

**Generation of VZV<sub>Luc</sub>.** It is difficult to monitor VZV replication in vivo. This problem can be solved by the addition of the luciferase gene to the VZV genome. Luciferase has been widely used as a reporter gene for transcriptional regulation studies. Its application has expanded to in vivo bioluminescence imaging in studies of bacterial and viral infection (9).

To generate a VZV<sub>Luc</sub> strain, a firefly luciferase expression cassette was inserted into the intergenic region between ORF65 and ORF66 of the VZV<sub>BAC</sub> genome. This clone was then transfected into MeWo cells to produce the VZV<sub>Luc</sub> strain. The properties of VZV<sub>Luc</sub> were analyzed. Growth curve analysis was first performed and showed that VZV expressing luciferase grows like its parental VZV<sub>BAC</sub> (data not shown). The luciferase activity from infected cells was then measured. The cells infected by VZV<sub>Luc</sub> produced high levels of luciferase activity, while the cells infected with VZV<sub>BAC</sub> did not (Fig. 2A). Bioluminescence from VZV<sub>Luc</sub>-infected cells was then visualized and measured using IVIS (Xenogen) imaging (22). MeWo cells were grown in six-well culture dishes and infected

with either VZV<sub>BAC</sub> (Fig. 2B, upper panel, two left wells) or VZV<sub>Luc</sub> (Fig. 2B, upper panel, two right wells). Three days postinfection, many green fluorescent plaques were observed for all wells, using fluorescence microscopy (Fig. 2B, lower panel), indicating that the cells were efficiently infected by both viruses. When the substrate of luciferase, D-luciferin, was added to the culture medium, strong bioluminescence was detected only from VZV<sub>Luc</sub>-infected cells (Fig. 2B, upper panel, two right wells), not from VZV<sub>BAC</sub>-infected cells (Fig. 2B, upper panel, two left wells).

Using bioluminescence to quantify growth kinetics of VZV would significantly reduce the effort and increase the accuracy of the infectious center assay. We investigated whether bioluminescence intensity correlated with viral titers. Growth curves of VZV<sub>Luc</sub> were compared using the conventional infectious center assay and the bioluminescence assay. For the infectious center assay, 21 wells were used. The contents of three wells were collected each day for 7 days. The titer of each sample was determined to produce a growth curve (Fig. 2C, black curve). For the bioluminescence assay, only three wells of infected cells were used for the entire experiment. The bioluminescence from infected cells was measured each day for 7 days, and a growth curve was generated. After 7 days of infection, the signals started to slowly decline due to deterioration of the cultured cells. As shown in Fig. 2C (green curve), these two curves correlated well, indicating that semiquantifying bioluminescence can be an alternative way to measure viral titers and used for growth curve assays.

To determine whether the BAC vector in the VZV genome has any effect on viral growth, the growth curves of VZV<sub>Luc</sub> with and without the BAC vector were compared using bioluminescence assay. As shown in Fig. 2D, both viruses replicated equally well, indicating that the BAC vector has no discernible effect on VZV replication *in vitro*.

#### Live-image analysis of VZV replication with SCID-hu mice.

Since VZV is restricted to human cells, mouse models for VZV studies are limited to those that engraft human tissues in immunodeficient mice. The SCID-hu mouse model is well established for studying VZV replication and determinants of tissue tropism (16); however, acquiring data has been hampered by having to euthanize the mice to measure virus growth. Sampling VZV-infected thymus-liver implants in the SCID-hu model has usually been done weekly or, at most, every 4 days. Moreover, the implants are different sizes, and so viral titers vary widely from animal to animal. To increase the sampling frequency and accuracy and, more importantly, to directly monitor VZV growth in live animals, we employed an IVIS, the SCID-hu thymus-liver mouse model, and VZV<sub>Luc</sub> to measure VZV spread *in vivo* each day for 1 week in the same mouse. The luciferase provides a visible marker for VZV in human tissues within living animals. Human fetal thymus and liver tissues were implanted under the left mouse kidney capsule. Two to three months later, the implants developed into a thymus-like organ consisting mainly of T cells. Viruses were grown in MeWo cells, and three SCID-hu mice with thymus-liver implants were inoculated by direct injection of a VZV-infected cell suspension. At different days postinoculation, the VZV replication *in vivo* was observed using an IVIS at 10 min after intraperitoneal injection of the SCID-hu mice with luciferin substrate. Bioluminescence was easily detected over the




FIG. 3. Measuring VZV<sub>Luc</sub> replication in SCID-hu mice. (A) Replication and progression of VZV<sub>Luc</sub> in human thymus-liver implants in SCID mice. Three SCID-hu mice implanted with thymus-liver implants were inoculated with VZV<sub>Luc</sub>. Using IVIS imaging, each mouse was scanned daily (from day 0 to day 8). Measurements were taken 10 min after intraperitoneal injection with D-luciferin substrate. Only images from mouse C are shown. Warmer colors indicate higher viral load; cooler colors indicate lower viral load. (B) VZV growth curves *in vivo*. Bioluminescence in three SCID-hu mice from the above experiment was measured, and VZV growth curves in human thymus-liver implants were generated.

left flank of each of the three infected SCID-hu mice where the thymus-liver implants were located under the kidney capsule, demonstrating that the replication of VZV<sub>Luc</sub> can be monitored in living animals. Photon emissions from the infected implants were converted into a pseudocolored image (Fig. 2E). The color scale indicated regions of low emissions in purple and blue and high emissions in yellow and red. VZV was limited to the thymus-liver implants and did not transfer into the peritoneum or other organs, which was expected for this human-restricted virus. Notably, the average background emissions were similarly low for uninfected areas of inoculated mice (photon flux =  $2,229 \pm 510$  photons/s/cm<sup>2</sup>/steradian) and over the kidney of a mock-inoculated control mouse (photon flux =  $2,363 \pm 334$  photons/s/cm<sup>2</sup>/steradian). The boundaries of a region of interest were manually set to closely border the luminescent area in each mouse. Measurements of total photon flux were used as an indicator of VZV infection. This result demonstrates that VZV<sub>Luc</sub> spread can be monitored and quantified *in vivo* using an IVIS.

**In vivo growth curve analysis of VZV.** VZV carrying a luciferase marker and the IVIS make measuring VZV replication *in vivo* possible. To measure VZV growth kinetics *in vivo*, three SCID-hu mice with human thymus-liver implants were inoculated with  $4 \times 10^3$  PFU VZV-infected MeWo cells. These infected mice were scanned using IVIS imaging. Live imaging commenced within 4 h after inoculation, designated day zero, and then each mouse was imaged daily for 8 days. As shown in Fig. 3A, photon emissions from the infected implants

increased daily until day 8 (only mouse C is shown). Each day, the bioluminescence signal from each mouse was quantified and plotted, and *in vivo* growth curves were generated (Fig. 3B). The kinetics of VZV<sub>Luc</sub> spread in three mice were similar and showed a general trend of exponential growth from day 1 to day 6 or 7, and then growth slowed or reached a steady state due to the fact that the viral infection within the limited implants had reached saturation (Fig. 3B). Based on these growth curves, VZV grew rapidly in human T cells *in vivo*, doubling approximately every 12 h, with maximal replication 7 days postinfection.

VZV<sub>Luc</sub> contains a large DNA insert for the BAC vector (~10 kb) and a luciferase expression cassette (~3 kb). Even though it had been shown that VZV carrying the BAC sequence grows like its parental virus *in vitro* (Fig. 1D and Fig. 2D), it was not known whether it would grow normally in thymus-liver implants. Thus, VZV<sub>Luc</sub> was compared to the isogenic strain VZV<sub>Luc(BAC)</sub>, from which the BAC sequences were removed from its genome by *Cre-lox* recombination. Growth curve analysis *in vivo* indicated that removing the BAC sequences did not appear to confer a growth advantage to the VZV<sub>Luc</sub> strain since there were no major differences in photon emissions observed (data not shown). These results were representative of two separate experiments that used thymus-liver implants from different donors. From these data, we concluded that the presence of the BAC sequence did not interfere with VZV replication in T cells.

**Generation of five deletion mutants of VZV.** To explore this novel luciferase VZV BAC system for studying VZV pathogenesis, five deletion mutants, from ORF0 (ORF0D) to ORF4 (ORF4D), were generated. To delete each of these ORFs from the VZV genome, a Kan<sup>r</sup> cassette was amplified by PCR using two primers containing 40-bp sequences homologous to the flanking sequences of each ORF. The PCR products were transformed into *E. coli* DY380 (32) harboring VZV<sub>Luc</sub> BAC and selected for chloramphenicol- and kanamycin-resistant colonies. In each transformant, the target ORF was replaced by the kanamycin cassette and deleted from its start to end sites (Fig. 4A). The correct deletion clones were checked first by comparing the HindIII digestion patterns with VZV<sub>Luc</sub> and ensuring that no abnormal deletions from the genomes were detected (Fig. 4B). Then the clones were confirmed by PCR analysis for the deletion of the target ORFs and the presence of adjacent ORFs (data not shown).

The mutants along with wild-type VZV<sub>Luc</sub> DNA were then transfected into MeWo cells to generate VZV deletion mutant viruses. For the clones with deletions of ORF1, ORF2, and ORF3 and parental VZV<sub>Luc</sub>, VZV plaques appeared between 3 and 5 days posttransfection, and recombinant virus grew like wild-type virus. The plaques from ORF0 deletion DNA developed significantly slower, resulting in smaller plaques. The ORF4 deletion DNA never produced any viruses after multiple transfections. These results suggested that for infection of MeWo cells, VZV ORF1, ORF2, and ORF3 are dispensable, ORF0 is required for optimal viral growth, and ORF4 is essential.

**Analysis of five VZV deletion mutants.** Four VZV deletion mutant strains, ORF0D, ORF1D, ORF2D, and ORF3D, were amplified in culture, and titers were determined. Their growth properties in MeWo cells were compared with those of their

parental VZV<sub>Luc</sub> strain. One hundred PFU of each mutant virus and wild-type virus was plated with fresh MeWo cells in 35-mm tissue culture wells in triplicate. Bioluminescence was recorded each day postinfection for 7 days using IVIS imaging after D-luciferin substrate was added to the wells for 10 min. Total photon counts from each well were measured, data from triplicates were averaged, and the growth curves of these viruses were generated. As shown in Fig. 4C, the ORF2D mutant grew as well as the wild type, and the ORF1D and ORF3D mutants grew slightly slower. In contrast, the ORF0D mutant showed a growth defect in MeWo cells, with slower kinetics and 10-fold less growth than wild-type and other mutant viruses.

The mutant viruses were tested in parallel with the VZV<sub>Luc</sub> strain in the SCID-hu model for their replication in human thymus-liver implants *in vivo*. Bioluminescence was measured at 4 h after inoculation and every day after for 7 days. For this rapid screening of *in vivo* phenotypes, three to five implants were inoculated with each virus. Most large implants produced strong and durable signals, while some small implants gave low or near-background signals. In addition, one mouse died on day 2. The poor signals due to small implants were removed from the data set, and the reliable numbers were averaged and used to generate *in vivo* growth curves of mice inoculated with different virus strains. As shown in Fig. 4D, mutant viruses ORF1D and ORF2D did not have a discernible growth defect in thymus-liver implants, and the ORF3D virus grew slightly, but not significantly, slower than the wild-type virus. Like wild-type VZV, these deletion mutants produced photon flux values of about 10<sup>6</sup> by 3 to 4 days after infection. In contrast, the implants inoculated with the ORF0D virus produced photon flux values that were approximately 100-fold (2 logs) less than those of VZV<sub>Luc</sub> or the other mutants. The rate of increase for ORF0D luminescence was lower, with the peak values obtained on day 5, and then levels declined. This defect of ORF0D *in vivo* is consistent with its defect *in vitro*, except that a more severe defect was observed.

**Rescue of ORF0 and ORF4 growth defects.** To prove that the growth defects observed with the ORF0 and ORF4 mutants are due to the functions of the deleted genes rather than potential mutations in other regions of the genome, ORF0R and ORF4R viruses rescue were generated. ORF0 and ORF4 sequences were first amplified by PCR and cloned into pGEM-zeo-loxP. Both clones were confirmed by sequencing analysis. These wild-type ORF0 and ORF4 sequences were introduced back to ORF0D and ORF4D genomes, respectively, by homologous recombination. The rescued clones were confirmed by their antibiotic properties, HindIII digestions (Fig. 4B), and PCR analysis. ORF0R and ORF4R were then generated by transfection. Growth curve analysis using bioluminescence assays *in vitro* indicated that both ORF0R and ORF4R viruses fully recovered their growth defects of the deletion viruses and grew as well as the wild-type virus (Fig. 4E). These results confirm that ORF0 is required for optimal viral replication and that the ORF4 sequence is essential.

To further confirm the growth defect of ORF0D, and also to verify the correlation between the bioluminescence assay and the infectious center assay, 100 PFU of wild-type, ORF0 deletion (ORF0D), and ORF0D rescue (ORF0R) viruses were used to infect two sets of MeWo cells in triplets, as detailed in




FIG. 4. Analysis of VZV ORF0 to ORF4. (A) Schematic diagram of the genomic organization of VZV ORF0 to ORF5 (1). Each ORF, from 0 to 4, was replaced by a  $Kan^r$  expression cassette to generate the deletion mutant as indicated for ORF4 (2). To create a rescue virus for the ORF4 deletion, ORF4 was cloned into pGEM-zeo-loxP, and the loxP-zeo-ORF4 cassette was amplified by PCR and used to replace the  $Kan^r$  cassette by homologous recombination (3). The zeocin-resistant gene ( $Zeo^r$ ) can be removed from the viral genome by introducing Cre recombinase (4). (B) Digestion analysis of VZV wild-type and recombinant viral BAC clones. VZV DNA from the wild type (WT), the ORF4 deletion clones (0D to 4D), and the ORF0D and ORF4D rescue clones (0R and 4R) was digested with HindIII and loaded onto a 0.5% agarose gel. In order to clearly show both smaller fragments and large fragments, two photos were taken. The lower panel was taken at an earlier time, and the upper panel was taken at a later time. Sizing markers (MR) are indicated at the left. (C) Growth curve analysis of VZV deletion mutants in vitro. One hundred PFU of each deletion mutant and VZV<sub>Luc</sub> (WT) were used to infect MeWo cells in six-well dishes in triplicate. Luminescence was measured using IVIS every day for 7 days after D-luciferin was applied to the cultured media. Total photon flux in each well (photons/s/cm<sup>2</sup>/steradian) was measured, and the values from triplicates were averaged. Growth curves were generated when the averaged photon counts for each day were plotted. (D) Growth curve analysis of VZV deletion mutants in vivo. SCID-hu mice with thymus-liver implants were inoculated with  $4 \times 10^3$  PFU VZV<sub>Luc</sub> or VZV deletion mutant strains as indicated. VZV replication was measured by IVIS daily for 1 week as photon flux in the regions of interest above the thymus-liver implants. Each line represents an average of data from 2 or 3 mice. An uninfected SCID-hu thymus-liver mouse was injected with D-luciferin, and the background luminescence was measured (pink line). (E) Growth curve analysis of VZV ORF0 and ORF4 deletion rescue viruses in vitro. The conditions in this assay were same as those described for panel B. (F) Growth curve comparison of measurements by luminescence assay and infectious center assay. MeWo cells were grown in six-well dishes in triplicate. The cells were infected with 100 PFU of wild-type (WT), ORF0 deletion (ORF0D), and ORF0D rescue (ORF0R) viruses, respectively. Growth curve analyses were carried out by luminescence assays (LA) and infectious center assays (IA) as described above. Total photon counts in each well were measured using IVIS, averaged, and plotted on the left. Total plaques per well were counted, averaged, and plotted on the right.

Materials and Methods. Comparison of the growth curves generated from both assays are shown in Fig. 4F. Both assays were correlated well for the growth of wild-type and ORF0R viruses, while for the ORF0D viruses, the data from the bioluminescence assay were slightly higher than those from the infectious center assay. This experiment has shown further that viral

growth curves measured using both assays shared the same trend.

**Monitoring VZV<sub>Luc</sub> replication in the implanted human skin in SCID mice.** VZV<sub>Luc</sub> was also tested for its spread and detection in human fetal skin xenografts in vivo. Human skin tissues were introduced into SCID mice as described previ-




FIG. 5. Analysis of VZV ORF0D and ORF0R viruses in SCID mice with human skin implants. (A) The three panels show human fetal skin implants infected by VZV<sub>Luc</sub> and imaged at 15 dpi. ORF0D right (R), the right implant was infected with the ORF0 deletion mutant. The bioluminescence signal is significantly lower than that of its rescue virus. ORF0R left (L) and R, left and right implants were infected with the rescue virus of the ORF0 deletion mutant. High luciferase activities were detected in these implants. (B) Growth curve analysis of ORF0D (red circles), ORF0R (brown circles), and wild-type (WT, blue circles) viruses in the human skin tissues implanted in SCID mice. The implants without inoculation of VZV were used as a negative control (Mock, green triangles). Each curve was generated by averaging data from three implants. One set of data points is shown for a control of WT and Mock infection.

ously (17). Four weeks after implantation, the VZV<sub>Luc</sub> strain and the ORF0D mutant and its rescue, ORF0R, viruses were inoculated in the skin tissues, and viral growth was monitored every 2 or 3 days for 15 days, using an IVIS. The wild-type and ORF0R viruses grew well and distinguishably from each other in the skin implants, whereas the ORF0D mutant grew significantly slower (Fig. 5).

## DISCUSSION

To date, knowledge of the molecular mechanisms of VZV pathogenesis remains relatively limited in comparison to that of other herpesviruses. Due to some unique features of this virus, such as its highly cell-associated nature in cell culture, genetic analysis based on conventional virological techniques, including plaque purification and high-multiplicity infections, becomes troublesome and challenging. To facilitate mutant virus generation, a VZV cosmid system derived from the pOka strain has been developed (6, 21). Cosmid-based mutagenesis has become a prevailing method to make genetically altered VZV recombinants. The entire genome of the pOka strain has been cloned as a VZV BAC previously (18) and in this study. Since cotransfection and homologous recombination after transfection are not required, recombinant VZVs can be produced efficiently.

Low-copy VZV BAC can be maintained in *E. coli recA* mutant strains (such as DY380 and DH10B) in a highly stable manner. The VZV BAC system allows for propagation of VZV DNA in *E. coli*, thus avoiding continual growth in cultured cells and preventing loss of VZV virulence. The VZV BAC system also allows easy DNA isolation from large volumes of bacterial culture. After multiple rounds of propagation and mutagenesis in *E. coli*, no detectable additional deletions or rearrangements of VZV genome were found. Sequencing analysis of ORF62, a large gene at ~3.9 kb, indicated that no mutations were introduced into this ORF in the VZV BAC DNA. The growth kinetics indicated that the VZV virus generated from BAC

DNA behaves indistinguishably from its parental pOka strain both in vitro and in vivo.

While the design of VZV BAC allows seamless removal of the 10-kb BAC vector sequence between two flanking *loxP* sites when VZV BAC DNA is cotransfected with a Cre expression plasmid into mammalian cells, growth curve analysis illustrated that VZV with and without the BAC vector have identical growth kinetics both in vitro and in vivo (Fig. 1D, Fig. 2D, and data not shown). This might be due to the fact that VZV has the smallest genome size compared with that of other human herpesviruses, and therefore its virion can tolerate extra DNA sequences in addition to its own genome without compromising viral replication. Furthermore, the GFP reporter gene embedded in this BAC vector and therefore future experimentation including plaque quantification and microscopy of viral infection are favorably enhanced and benefit from this visible feature of the VZV BAC virus replication and spread. If the BAC vector and the GFP have any interference with particular experiments, they can easily be removed from the viral genome by cotransfection of a Cre expression plasmid with VZV BAC DNA when VZV is produced.

The SCID-hu mouse model has been well developed to examine VZV pathogenesis and immunobiology in vivo (1, 3, 13, 33). If genetic changes are not essential for viral growth, VZV mutants can be further studied in SCID-hu mice with human thymus-liver and skin xenografts to illustrate the specific gene functions during VZV replication in fully differentiated human cells in vivo. However, acquiring quantitative data has been thwarted by the necessity of euthanizing the mice to measure viral titer. Sampling VZV-infected thymus-liver implants in the SCID-hu model has usually been done weekly or, at most, every 4 days. Moreover, VZV growth kinetics is rapid, and in order to monitor viral growth in vivo in a more accurate manner, more frequent sampling is required. Additionally, viral titers from one implant to another are quite different; a large number of SCID-hu mice are required to test each recombinant virus in order to obtain reliable data. Titra-

TABLE 1. Summary of genetic analysis of VZV ORF0 to ORF4

ORF	Location	Size (bp)	Gene product	HSV-1 orthologue	Mutant growth property		
					In vitro	SCID-hu	Rescue
0	173–562	390	Putative transmembrane protein	UL56	Slow	Slow	Normal
1	589–915 <sup>a</sup>	327	Putative transmembrane protein	None	Normal	Normal	N/A <sup>b</sup>
2	1134–1850	717	Unknown	None	Normal	Normal	N/A
3	1908–2447 <sup>a</sup>	540	Unknown	UL55	Normal	Normal	N/A
4	2783–4141 <sup>a</sup>	1,359	Posttranscriptional regulator	UL54	Essential	N/A	Normal

<sup>a</sup> Encoded on the bottom strand.

<sup>b</sup> N/A, not applicable.

tion of VZV from the implants does not accurately reflect virus spread. Because the skin tissue is very tough, it cannot be dispersed to a single-cell suspension. Thymus-liver implants contain many dead T cells that were killed by VZV infection and are no longer infectious. In previous studies, the titer of VZV from infected implants (skin and thymus-liver) was not considered quantitative, and the kinetics of VZV replication was unclear. These factors have impeded efforts to study large numbers of VZV variants and have made it difficult to discern the minor phenotypic differences leading to pathogenesis.

To overcome the above-described obstacles, a luciferase expression cassette was inserted between ORF65 and ORF66 to achieve generation of the VZV<sub>Luc</sub> BAC. First, growth kinetic analyses showed that the presence of a luciferase gene did not interfere with VZV replication, both in vitro and in vivo. The growth kinetic analysis based on conventional infectious center assay and luciferase activity assays demonstrated that the intensities of bioluminescent signals correlate with virus titers (Fig. 2C and Fig. 4F). This enables subtle detection of viral replication as well as location over the course of infection in a real-time and noninvasive manner in human tissues. Moreover, in case a certain VZV variant bears a defect that alters the syncytium formation, the new luciferase activity approach will be superior to the conventional method because luciferase activities are indicators of viral loads instead of the number of infected cells. Therefore, the combination of VZV<sub>Luc</sub> and IVIS imaging not only makes monitoring VZV replication in live animals possible but also significantly reduces the number of SCID-hu mice required for experiments. Furthermore, this approach greatly increases experimental reproducibility and reliability. VZV<sub>Luc</sub> and IVIS imaging will be a very useful system with which to study the nature of VZV mutants. Although the bioluminescence assay has its advantages, this does not mean it could replace the infectious center assay. Rather, it serves as an easy alternative approach and a complement to the conventional assays. The nature of viral growth phenotypes found by bioluminescence assay should be further scrutinized using other methods.

VZV carries at least 70 unique ORFs, and many of their functions remain mysterious. Among those VZV ORFs, ORF0 (S/L), ORF1, ORF2, ORF13, ORF32, and ORF57 do not have homologs in herpes simplex virus (HSV) (8). This newly developed VZV<sub>Luc</sub> BAC clone can be efficiently altered by using the inducible lambda prophage system, providing homologous recombination in *E. coli* DY380 (32). The combination of VZV BAC technology, the SCID-hu model, the VZV genome carrying the luciferase gene, and live imaging forms a system

with the potential capacity to generate and study much greater numbers of VZV strains than has been possible until now. In this paper, we reported the analysis of the small VZV genomic region, from ORF0 to ORF4, summarized in Table 1.

VZV ORF0, also known as ORFS/L, encodes a putative protein and has been suggested to play a role in altering cell adhesion molecules in infected cells (12). Intriguingly, we have observed a significant slow-growth phenotype in both cultured cells and SCID-hu T cells/skin xenografts, and the growth defect could be fully rescued when the wild-type copy was introduced back into its native site. Our results indicate that VZV ORF0 is a potential virulence gene, while the mechanism needs to be further investigated. It is possible that the deletion of ORF0 could interfere with end-of-genome functions rather than the function of the protein. This could be investigated by inserting stop codons in ORF0 rather than deleting the whole sequence.

VZV ORF1 encodes a putative membrane protein and has been shown to be dispensable for viral replication in vitro (7). VZV ORF2 encodes a phosphoprotein located in the membrane of infected cells and has been shown to be dispensable for viral replication in vitro and for establishment of latency in the cotton rat model (25). In this study, we have achieved similar results and, furthermore, have illustrated that VZV ORF1 and ORF2 are dispensable for viral replication in vivo. VZV ORF3 has not been studied before, while its HSV homolog, UL55, has been shown to be dispensable for viral replication and for establishment of latency (19). Our results have suggested that VZV ORF3 is dispensable for viral growth both in vitro and in vivo. VZV ORF4 encodes an immediate-early regulator that transactivates other viral genes in all three kinetic classes in a transient-expression system and enhances another immediate-early protein's, IE62's, transactivation activity. It has been shown that ORF4 is essential for viral replication and for establishment of latency in the cotton rat model (5, 24). Using the VZV<sub>Luc</sub> BAC system, a consistent result has been obtained in this study, serving as a control experiment for the system. Results from genetic analysis of ORF0 to ORF4 have also fully validated the use of the novel luciferase VZV BAC system to efficiently generate recombinant VZV variants and carry out subsequent viral growth kinetic analysis both in vitro and in vivo.

Future studies include functionally profiling the entire VZV genome, using this versatile and robust VZV<sub>Luc</sub> BAC system, identifying VZV tropism factors, and performing large-scale anti-VZV compound screening. Surely the principle could be expanded and applied to broader virological research.

## ACKNOWLEDGMENTS

We thank C. Patterson and A. Chu for critically reading the manuscript.

This work was supported by NIH grants AI050709 (H.Z.), AI052168 (J.F.M.), and AI053846 (A.M.A.).

## REFERENCES

- Arvin, A. M. 2001. Varicella-zoster virus, p. 2731–2767. *In* D. M. Knipe and P. M. Howley (ed.), *Fields virology*, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
- Ball, K. D., and J. T. Trevors. 2002. Bacterial genomics: the use of DNA microarrays and bacterial artificial chromosomes. *J. Microbiol. Methods* **49**:275–284.
- Besser, J., M. H. Sommer, L. Zerboni, C. P. Bagowski, H. Ito, J. Moffat, C.-C. Ku, and A. M. Arvin. 2003. Differentiation of varicella-zoster virus ORF47 protein kinase and IE62 protein binding domains and their contributions to replication in human skin xenografts in the SCID-hu mouse. *J. Virol.* **77**:5964–5974.
- Boehncke, W. H. 1999. The SCID-hu xenogeneic transplantation model: complex but telling. *Arch. Dermatol. Res.* **291**:367–373.
- Cohen, J. I., T. Krogmann, J. P. Ross, L. Pesnicak, and E. A. Prikhod'ko. 2005. Varicella-zoster virus ORF4 latency-associated protein is important for establishment of latency. *J. Virol.* **79**:6969–6975.
- Cohen, J. I., and K. E. Seidel. 1993. Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. *Proc. Natl. Acad. Sci. USA* **90**:7376–7380.
- Cohen, J. I., and K. E. Seidel. 1995. Varicella-zoster virus open reading frame 1 encodes a membrane protein that is dispensable for growth of VZV in vitro. *Virology* **206**:835–842.
- Cohen, J. I., and S. E. Straus. 2001. Varicella-zoster virus and its replication, p. 2707–2730. *In* D. M. Knipe and P. M. Howley (ed.), *Fields virology*, vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA.
- Doyle, T. C., S. M. Burns, and C. H. Contag. 2004. In vivo bioluminescence imaging for integrated studies of infection. *Cell Microbiol.* **6**:303–317.
- Gilden, D. H., B. K. Kleinschmidt-DeMasters, J. J. LaGuardia, R. Mahalingam, and R. J. Cohrs. 2000. Neurologic complications of the reactivation of varicella-zoster virus. *N. Engl. J. Med.* **342**:635–645.
- Hambleton, S., and A. A. Gershon. 2005. Preventing varicella-zoster disease. *Clin. Microbiol. Rev.* **18**:70–80.
- Kemble, G. W., P. Annunziato, O. Lungu, R. E. Winter, T.-A. Cha, S. J. Silverstein, and R. R. Spaete. 2000. Open reading frame S/L of varicella-zoster virus encodes a cytoplasmic protein expressed in infected cells. *J. Virol.* **74**:11311–11321.
- Ku, C.-C., J. Besser, A. Abendroth, C. Grose, and A. M. Arvin. 2005. Varicella-zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. *J. Virol.* **79**:2651–2658.
- Mallory, S., M. Sommer, and A. M. Arvin. 1997. Mutational analysis of the role of glycoprotein I in varicella-zoster virus replication and its effects on glycoprotein E conformation and trafficking. *J. Virol.* **71**:8279–8288.
- Marchini, A., H. Liu, and H. Zhu. 2001. Human cytomegalovirus with IE-2 (UL122) deleted fails to express early lytic genes. *J. Virol.* **75**:1870–1878.
- Moffat, J. F., and A. M. Arvin. 1999. Varicella-zoster virus infection of T cells and skin in the SCID-hu mouse model, p. 973–980. *In* M. A. Sande and O. Zak (ed.), *Handbook of animal models of infection: experimental models in antimicrobial chemotherapy*. Academic Press, San Diego, CA.
- Moffat, J. F., M. D. Stein, H. Kaneshima, and A. M. Arvin. 1995. Tropism of varicella-zoster virus for human CD4<sup>+</sup> and CD8<sup>+</sup> T lymphocytes and epidermal cells in SCID-hu mice. *J. Virol.* **69**:5236–5242.
- Nagaike, K., Y. Mori, Y. Gomi, H. Yoshii, M. Takahashi, M. Wagner, U. Koszinowski, and K. Yamanishi. 2004. Cloning of the varicella-zoster virus genome as an infectious bacterial artificial chromosome in *Escherichia coli*. *Vaccine* **22**:4069–4074.
- Nash, T. C., and J. G. Spivack. 1994. The UL55 and UL56 genes of herpes simplex virus type 1 are not required for viral replication, intraperitoneal virulence, or establishment of latency in mice. *Virology* **204**:794–798.
- Netterwald, J., S. Yang, W. Wang, S. Ghanny, M. Cody, P. Soteropoulos, B. Tian, W. Dunn, F. Liu, and H. Zhu. 2005. Two gamma interferon-activated site-like elements in the human cytomegalovirus major immediate-early promoter/enhancer are important for viral replication. *J. Virol.* **79**:5035–5046.
- Niizuma, T., L. Zerboni, M. H. Sommer, H. Ito, S. Hinchliffe, and A. M. Arvin. 2003. Construction of varicella-zoster virus recombinants from parent Oka cosmids and demonstration that ORF65 protein is dispensable for infection of human skin and T cells in the SCID-hu mouse model. *J. Virol.* **77**:6062–6065.
- Rice, B. W., M. D. Cable, and M. B. Nelson. 2001. In vivo imaging of light-emitting probes. *J. Biomed. Opt.* **6**:432–440.
- Sato, B., H. Ito, S. Hinchliffe, M. H. Sommer, L. Zerboni, and A. M. Arvin. 2003. Mutational analysis of open reading frames 62 and 71, encoding the varicella-zoster virus immediate-early transactivating protein, IE62, and effects on replication in vitro and in skin xenografts in the SCID-hu mouse in vivo. *J. Virol.* **77**:5607–5620.
- Sato, B., M. Sommer, H. Ito, and A. M. Arvin. 2003. Requirement of varicella-zoster virus immediate-early 4 protein for viral replication. *J. Virol.* **77**:12369–12372.
- Sato, H., L. Pesnicak, and J. I. Cohen. 2002. Varicella-zoster virus open reading frame 2 encodes a membrane phosphoprotein that is dispensable for viral replication and for establishment of latency. *J. Virol.* **76**:3575–3578.
- Shiraki, K., Y. Yoshida, Y. Asano, K. Yamanishi, and M. Takahashi. 2003. Pathogenetic tropism of varicella-zoster virus to primary human hepatocytes and attenuating tropism of Oka varicella vaccine strain to neonatal dermal fibroblasts. *J. Infect. Dis.* **188**:1875–1877.
- Swaminathan, S., H. M. Ellis, L. S. Waters, D. Yu, E. C. Lee, D. L. Court, and S. K. Sharan. 2001. Rapid engineering of bacterial artificial chromosomes using oligonucleotides. *Genesis* **29**:14–21.
- Takahashi, M., T. Otsuka, Y. Okuno, Y. Asano, and T. Yazaki. 1974. Live vaccine used to prevent the spread of varicella in children in hospital. *Lancet* **2**:1288–1290.
- Taylor, S. L., and J. F. Moffat. 2005. Replication of varicella-zoster virus in human skin organ culture. *J. Virol.* **79**:11501–11506.
- Volpi, A. 2005. Varicella immunization and herpes zoster. *Herpes* **12**:59.
- Wang, W., C. E. Patterson, S. Yang, and H. Zhu. 2004. Coupling generation of cytomegalovirus deletion mutants and amplification of viral BAC clones. *J. Virol. Methods* **121**:137–143.
- Yu, D., H. M. Ellis, E. C. Lee, N. A. Jenkins, N. G. Copeland, and D. L. Court. 2000. An efficient recombination system for chromosome engineering in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **97**:5978–5983.
- Zerboni, L., C. C. Ku, C. D. Jones, J. L. Zehnder, and A. M. Arvin. 2005. Varicella-zoster virus infection of human dorsal root ganglia in vivo. *Proc. Natl. Acad. Sci. USA* **102**:6490–6495.